Document:

Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This Securities
Purchase Agreement (the “Agreement”) is entered into and effective as of February 27, 2019 (the
“Effective Date”), by and between DPW Holdings, Inc., a Delaware corporation
(the “Company”) and Ault & Company, Inc., a Delaware corporation (including its designees, successors
and assigns, the “Investor”).

 

RECITALS

 

A.       The
parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue to Investor, and Investor
shall purchase from the Company, from time to time as provided herein, up to 2,500 shares of Series C Convertible Redeemable Preferred
Stock (the “Preferred Shares”) at a purchase price equal to $1,000 per share of Series C Preferred Stock ($2,500,000
in the aggregate); and

 

B.       The
offer and sale of the Preferred Shares provided for herein are being made without registration under the Securities Act, in reliance
upon the provisions of Section 4(a)(2) of the Securities Act, Regulation D promulgated under the Securities Act, and such other
exemptions from the registration requirements of the Securities Act as may be available with respect to any or all of the purchases
of Preferred Shares to be made hereunder.

 

AGREEMENT

 

In consideration of the
premises, the mutual provisions of this Agreement, and other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, Company and Investor agree as follows:

 

ARTICLE 1

DEFINITIONS

 

In addition to the terms
defined elsewhere in this Agreement, the following terms have the meanings indicated in this Article I:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to Investor,
without limitation, any Person owning, owned by, or under common ownership with Investor, and any investment fund or managed account
that is managed on a discretionary basis by the same investment manager as Investor will be deemed to be an Affiliate.

 

“Agreement”
means this Securities Purchase Agreement including the exhibits and schedules hereto.

 

“Balance Sheet
Date” has the meaning set forth in Section 3.1(f)(i).

 

“Charter Documents”
has the meaning set forth in Section 3.1(a).

 

“Closing”
means any one of (i) the Transaction Closing as set forth in Section 2.2(a) and (ii) each Tranche Closing as set forth in
Section 2.4(e)(v).

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common Stock”
means the Class A Common Stock, par value $0.001 per share, of the Company, and any replacement or substitute thereof, or any share
capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common
Stock.

 

“Contracts”
means any and all contracts, agreements, commitment, franchises, understandings, arrangements, leases, licenses, registrations,
authorizations, easements, servitudes, rights of way, mortgages, bonds, notes, guaranties, Encumbrances, evidence of indebtedness,
approvals or other instruments or undertakings to which such person is a party or to which or by which such person or the property
of such person is subject or bound, whether written or oral and whether or not entered into in the ordinary and usual course of
the Person’s business, excluding any Permits, provided that each such Contract shall provide for the payment of no less than
$15,000.

 

    	 	 	 

    	 

    

 

“Control Person”
means each director, executive officer, promoter, and such other Persons as may be deemed in control of the Company, as such term
is defined by Rule 405 under the Securities Act.

 

“Delisting Period”
means any time during the term of this Agreement, that the Common Stock is not listed for and actively and/or regularly trading
on a Trading Market, or is suspended or delisted with respect to the trading of the shares of Common Stock on a Trading Market.

 

“Disclosure Schedules”
means the disclosure schedules of the Company delivered concurrently herewith, attached hereto, and incorporated herein by reference.
The Disclosure Schedules shall contain no material non-public information.

 

“DTC”
means The Depository Trust Company, or any successor performing substantially the same function for Company.

 

“DWAC Shares”
means, except as expressly stated otherwise herein, all shares of Common Stock issued or issuable to Investor or any Affiliate,
successor or assign of Investor pursuant to any of the Transaction Documents, all of which shall be (a) issued in electronic form,
(b) freely tradable and without restriction on resale, and (c) timely credited by Company to the specified Deposit/Withdrawal at
Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar program hereafter
adopted by DTC performing substantially the same function, in accordance with irrevocable instructions issued to and countersigned
by the Transfer Agent, in the form attached hereto as Exhibit C or in such other form agreed upon by the parties.

 

“Encumbrances”
means any and all claims, liabilities and obligations and all liens, pledges, charges, mortgages, security interests, restrictions,
leases, licenses, easements, liabilities, claims, encumbrances, preferences, priorities or rights of others of every kind and description.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Firm”
has the meaning set forth in Section 3.1(f)(i).

 

“Financial Statements”
has the meaning set forth in Section 3.1(f)(i).

 

“FINRA”
means the Financial Industry Regulatory Authority, Inc.

 

“Fundamental Transaction”
means and shall be deemed to have occurred at such time upon any of the following events:

 

(i)   
    a consolidation, merger or other business combination or event or transaction, following which the
holders of Common Stock immediately preceding such consolidation, merger, combination or event either (a) no longer hold a
majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the
Company (a “Change in Control”);

 

(ii)       the
sale or transfer of all or substantially all of the Company’s assets; or

 

(iii)      a
purchase, tender or exchange offer made to the holders of the outstanding shares of Common Stock.

 

“GAAP”
means United States generally accepted accounting principles applied on a consistent basis during the periods involved.

 

“Governmental
Authority” means any nation or country (including but not limited to the United States) and any commonwealth, territory
or possession thereof and any government or governmental or regulatory, legislative, executive authority thereof, or commission,
department or political subdivision thereof, whether federal, state, regional, municipal, local or foreign, or any department,
board, bureau, agency, instrumentality or authority thereof, or any court or arbitrator (public or private), including, but not
limited to, the Commission and FINRA.

 

    	 	 -2 - 	 

    	 

    

 

“Intellectual
Property” means any patent, patent right, trademark, trademark right, trade name, trade name right, service mark, service
mark right, copyright and other proprietary intellectual property right and computer program.

 

“Investigation”
has the meaning set forth in Section 3.2(d)(vi).

 

“Knowledge”
means, with respect to any Person, (x) such Person is actually aware of such fact or matter or (y) such Person should reasonably
have been expected to discover or otherwise become aware of such fact or matter after reasonable investigation, and for purposes
hereof it shall be assumed that such Person has conducted a reasonable investigation of the accuracy of the representations and
warranties set forth herein.

 

“Leased Properties”
has the meaning set forth in Section 3.1(n)(ii).

 

“Legal Requirements”
means any and all laws (statutory, judicial or otherwise), ordinances, regulations, judgments, orders, directives, injunctions,
writs, decrees or awards of, and any Contracts with, any Governmental Authority, in each case as and to the extent applicable to
such person or such person’s business, operations or Properties.

 

“Liability”
means any liability, obligation or indebtedness of whatever kind or nature (whether known or unknown, whether asserted or unasserted,
whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become
due), including any liability for Taxes.

 

“Loss”
or “Losses” means any and all Liability, damages, fines, fees, penalties and expenses whether or not arising
out of litigation, including without limitation, interest, reasonable expenses of investigation, court costs, reasonable out-of-pocket
fees and expenses of attorneys, accountants and other experts or other reasonable out-of-pocket expenses of litigation or other
legal proceedings, incurred in connection with the rightful enforcement of rights under this Agreement against any party hereto,
and whether or not arising out of third party claims against an indemnified party.

 

“Material Adverse
Effect” means any material adverse effect on (i) the legality, validity or enforceability of any Transaction Document,
(ii) the results of operations, assets, business, prospects or financial condition of the Company and the Subsidiaries, taken as
a whole, or (iii) the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document.

 

“Material Agreement”
means any material loan agreement, financing agreement, equity investment agreement or securities instrument to which Company is
a party, any agreement or instrument to which Company and Investor or any Affiliate of Investor is a party, and any other material
agreement listed, or required to be listed, on any of Company’s reports filed or required to be filed with the Commission,
including without limitation Forms 10-K, 10-Q or 8-K.

 

“Maximum Tranche
Amount” means, subject to any other applicable limitations set forth in this Agreement, the Purchase Price less the amount
of any previously noticed and funded Tranches.

 

“Officer’s
Certificate” means a certificate in customary form reasonably acceptable to Investor, executed by an authorized officer
of the Company.

 

“Opinion”
means an opinion from Company’s independent legal counsel, in the form attached as Exhibit D or in such other
form agreed upon by the parties, to be delivered in connection with the Transaction Closing and any Tranche Closing.

 

“Permits”
means any and all permits, rights, approvals, licenses, authorizations, legal status, orders or Contracts under any Legal Requirement
or otherwise granted by any Governmental Authority.

 

    	 	 -3 - 	 

    	 

    

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Per Share Purchase
Price” means $1,000.00.

 

“Properties”
means any and all properties and assets (real, personal or mixed, tangible or intangible) owned or used by the Company.

 

“Purchase Price”
means Two Million Five Hundred Thousand Dollars ($2,500,000).

 

“Purchase Right”
with respect to any Person means any security, right, subscription, warrant, option or other Contract that gives the right to purchase
or otherwise receive or be issued any shares of capital stock or other equity interests of such Person or any security of any kind
convertible into or exchangeable or exercisable for any shares of capital stock or other equity interests of such Person.

 

“Records”
means all originals and copies of agreements, instruments, documents, deeds, books, records, files, corporate franchises, stock
record books, corporate books containing the minutes of meetings of directors and shareholders and any and all other data and information
within the possession of a party or any Affiliate thereof.

 

“Regulation D”
means Regulation D promulgated under the Securities Act.

 

“Required Approval”
means any approval of the NYSE American.

 

“Required Tranche
Documents” has the meaning set forth in Section 2.4(d).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect.

 

“Rule 144 Eligible”
means eligible for immediate resale under Rule 144 without limitation on the amount of securities sold under Rule 144(e).

 

“SEC Reports”
includes all reports required to be filed by the Company under the Securities Act and/or the Exchange Act, including pursuant to
Section 13(a) or 15(d) thereof, for the two (2) years preceding the Effective Date (or such shorter period as the Company was required
by law to file such material) and for the period in which this Agreement is in effect.

 

“Securities Act” means the
Securities Act of 1933, as amended.

 

“Series C Preferred
Stock” means shares of Series C Convertible Redeemable Preferred Stock, $0.001 par value per share, issuable pursuant
to the Certificate of Designations of Rights and Preferences in the form attached hereto as Exhibit A.

 

“Preferred Shares”
means the shares of Series C Preferred Stock being issued and sold to the Investor by the Company hereunder.

 

“Subsidiary”
means any Person the Company owns or controls, or in which the Company, directly or indirectly, owns a majority of the capital
stock or similar interest that would be disclosable pursuant to Regulation S-K, Item 601(b)(21).

 

“Tax”
means any and all taxes, charges, fees, levies or other assessments, including, without limitation, local and/or foreign income,
net worth, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental,
customs duties, share capital, franchise, profits, withholding, social security (or similar), unemployment, disability, real property,
personal property, sales, use, service, service use, transfer, registration, recording, ad valorem, value-added, alternative or
add-on minimum, estimated, or other taxes, assessments or charges of any kind whatsoever, including any interest, penalty, or addition
thereto, whether disputed or not.

 

    	 	 -4 - 	 

    	 

    

 

“Tax Return”
means any federal, state, local and foreign tax return, report or similar statement required to be filed with respect to any Tax
(including any attached Schedules), including, without limitation, any information return, claim for refund, amended return or
declaration of estimated Tax.

 

“Taxing Authority”
means the Internal Revenue Service and any other Governmental Authority responsible for the administration of any Tax.

 

“Termination Date”
means the earlier of (i) December 31, 2019, or (ii) the Tranche Closing Date on which the sum of the aggregate Tranche Purchase
Price for all Tranche Shares equals the Purchase Price.

 

“Trading Day”
means any day on which the Common Stock is traded on the Trading Market; provided that it shall not include any day on which the
Common Stock is (a) scheduled to trade for less than 5 hours, or (b) suspended from trading.

 

“Trading Market”
means the OTCQB, the OTCQX, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE American,
or the New York Stock Exchange, whichever is at the time the principal trading system, exchange or market for the Common Stock,
but does not include the OTC Pink Sheets inter-dealer electronic quotation and trading system.

 

“Tranche”
has the meaning set forth in Section 2.4(a).

 

“Tranche Closing”
has the meaning set forth in Section 2.4(e)(iv).

 

“Tranche Closing
Date” has the meaning set forth in Section 2.4(e)(ii).

 

“Tranche Notice”
has the meaning set forth in Section 2.4(b).

 

“Tranche Notice
Date” has the meaning set forth in Section 2.4(b).

 

“Tranche Purchase
Price” has the meaning set forth in Section 2.4(b), and shall be specified in writing by the Investor.

 

“Tranche Shares”
means the Preferred Shares that are purchased by Investor pursuant to a Tranche Notice.

 

“Transaction Documents”
means this Agreement, the other agreements and documents referenced herein, and the exhibits and schedules hereto and thereto.

 

“Transfer Agent”
means Computershare or any successor transfer agent for the Common Stock.

 

“Use of Proceeds
Certificate” means a certificate, in substantially the form attached as Exhibit E, signed by an officer
of the Company, setting forth how the Tranche Purchase Price will be applied by the Company.

 

ARTICLE 2

PURCHASE AND SALE

 

2.1          Agreement
to Purchase.  Subject to the terms and conditions herein and the satisfaction of the conditions to closing set forth
in this Article 2, the Company hereby agrees to issue to the Investor and the Investor hereby agrees to purchase, in its
sole and absolute discretion, up to 2,500 Preferred Shares in one or more Tranches in accordance with Section 2.4 below,
from the Company for the Tranche Purchase Price and to furnish to the Company the Tranche Purchase Price in consideration for
the Preferred Shares, in accordance with the terms of this Agreement.

 

    	 	 -5 - 	 

    	 

    

 

2.2          Closing;
Conditions to Closing.

 

(a)       Closing.
The closing of this Agreement (the “Transaction Closing”) shall be deemed to occur when this Agreement has been
duly executed by both Investor and the Company, and the other Conditions to the Closing set forth in Section 2.2(b) have
been met.

 

(b)       Company
Conditions to Closing. As a condition precedent to the Transaction Closing, all of the following (the “Company Conditions
to Closing”) shall have been satisfied prior to or concurrently with the Company’s execution and delivery of this
Agreement:

 

(i)       the
following documents shall have been delivered to the Investor: (A) this Agreement (including the Disclosure Schedules), executed
by the Company; (B) a Secretary’s Certificate as to (x) the resolutions of the Company’s board of directors authorizing
this Agreement and the Transaction Documents, and the transactions contemplated hereby and thereby, and (y) a copy of the Company’s
Charter Documents, and (C) a copy of the Company’s press release announcing the transactions contemplated by this Agreement
(all documents listed in this Section 2.2(b) are referred to herein as the “Closing Deliverables”);

 

(ii)       other
than for losses incurred in the ordinary course of business, there shall not have been any Material Adverse Effect on the Company
since the date of the last SEC Report filed by the Company, including but not limited to incurring material liabilities; and

 

(iii)       the
representations and warranties of the Company in this Agreement shall be true and correct in all material respects.

 

2.3          Share
Sufficiency. On the date of Closing, the Company shall have a sufficient number of duly authorized shares of Series C Preferred
Stock to be able to issue the Preferred Shares to the Investor.

 

2.4          Tranches
to Investor

 

(a)       Procedure
to Elect a Tranche. Subject to the Maximum Tranche Amount, the Purchase Price and the other conditions and limitations set
forth in this Agreement, at any time beginning on the Effective Date, the Investor may, in its sole and absolute discretion, elect
to exercise one or more individual purchases of Preferred Shares under this Agreement (each a “Tranche”) according
to the following procedure.

 

(b)       Delivery
of Tranche Notice. The Investor shall, from time to time in its sole and absolute discretion, deliver an irrevocable written
notice (the “Tranche Notice”), in the form attached hereto as Exhibit B, to the Company stating
that the Investor shall exercise a Tranche and stating the number of Preferred Shares which the Investor will purchase from the
Company at the Per Share Purchase Price, and the aggregate purchase price for such Tranche (the “Tranche Purchase Price”).
A Tranche Notice delivered by the Investor to the Company by 4:30 p.m. Eastern time on any Trading Day shall be deemed delivered
on the same day. A Tranche Notice delivered by the Investor to the Company after 4:30 p.m. Eastern time on any Trading Day, or
at any time on a non-Trading Day, shall be deemed delivered on the next Trading Day. The date that the Tranche Notice is deemed
delivered is the “Tranche Notice Date.” Each Tranche Notice shall be delivered via facsimile or electronic mail,
with confirming copy by overnight carrier, in each case to the address set forth after the signature page hereof.

 

(c)       Conditions
Precedent to Right to Deliver a Tranche Notice. The right of the Investor to deliver, from time to time or at any time, a Tranche
Notice for an amount up to the Purchase Price is subject to the satisfaction, on the date of delivery of such Tranche Notice, of
each of the following conditions:

 

(i)       the
Common Stock shall be listed for and currently trading on the Trading Market, and to the Company’s Knowledge there is no
notice of any suspension or delisting with respect the trading of the shares of Common Stock on such Trading Market;

 

(ii)       the
representations and warranties of the Company set forth in this Agreement shall be true and correct in all material respects as
if made on such date (except for any representations and warranties that are expressly made as of a particular date, in which case
such representations and warranties shall be true and correct as of such particular date), and no default shall have occurred under
this Agreement, or any other agreement with Investor or any Affiliate of Investor, or any other Material Agreement, and the Company
shall deliver an Officer’s Closing Certificate to such effect to Investor, signed by an officer of the Company;

 

    	 	 -6 - 	 

    	 

    

 

(iii)       other
than losses incurred in the ordinary course of business, there has been no Material Adverse Effect on the Company since the Commitment
Closing;

 

(iv)       the
Company is not, and will not be as a result of the applicable Tranche, in default of this Agreement, any other agreement with Investor
or any Affiliate of Investor, or any other Material Agreement;

 

(v)       there
is not then in effect any law, rule or regulation prohibiting or restricting the transactions contemplated in this Agreement or
any other Transaction Document, or requiring any consent or approval which shall not have been obtained, nor is there any pending
or threatened proceeding or investigation which may have the effect of prohibiting or adversely affecting any of the transactions
contemplated by this Agreement; no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits the transactions
contemplated by this Agreement, and no actions, suits or proceedings shall be in progress, pending or, to the Company’s knowledge
threatened, by any person (other than Investor or any Affiliate of Investor), that seek to enjoin or prohibit the transactions
contemplated by this Agreement;

 

(vi)       the
Company is in compliance with all requirements to maintain its then-current listing on the Trading Market; and

 

(vii)       the
Company has a sufficient number of duly authorized shares of Common Stock reserved for issuance in such amount as may be required
to fulfill its obligations pursuant to the Transaction Documents and any outstanding agreements with Investor and any Affiliate
of Investor, including without limitation all conversion shares issuable upon conversion of the Preferred Shares issued in connection
with such Tranche.

 

(d)       Documents
to be Delivered at Tranche Closing. The Closing of any Tranche and Investor’s options hereunder shall additionally be
conditioned upon the delivery, unless otherwise provided otherwise below, to Investor of each of the following (the “Required
Tranche Documents”) on or before the applicable Tranche Closing Date:

 

(i)       this
Agreement duly executed by the Company

 

(ii)       certificate(s)
evidencing a number of Preferred Shares equal to the Tranche Purchase Price divided by the Tranche Share Price shall have been
delivered to Investor or an account specified by the Investor for the Tranche Shares;

 

(iii)      the
Opinion;

 

(iv)      the
Officer’s Certificate, signed by an officer of the Company;

 

(v)  
    a Secretary’s Certificate executed by the Corporate Secretary of the Company;

 

(vi)      a
Use of Proceeds Certificate, signed by an officer of the Company, and setting forth how the Tranche Purchase Price will be applied
by the Company;

 

(vii)     the
delivery of all Conversion Shares on a timely basis in accordance with any conversion notice delivered to Company prior to the
Tranche Closing Date;

 

(viii)       Certificates
of Good Standing of the Company and each Subsidiary from each such entity’s jurisdiction of incorporation and any jurisdiction
in which any such entity is qualified to do business;

 

    	 	 -7 - 	 

    	 

    

 

(ix)      the
Required Approval for the issuance of the Tranche Shares shall have been obtained;

 

(x)       all
documents, instruments and other writings required to be delivered by the Company to Investor on or before the Tranche Closing
Date pursuant to any provision of this Agreement or in order to implement and effect the transactions contemplated herein.

 

(e)       Mechanics
of Tranche Closing.

 

(i)       On
or before any Tranche Closing, the Investor shall deliver to the Company the Tranche Purchase Price in cash or immediately available
funds as consideration for the purchase of the Tranche Shares pursuant to wire instructions delivered to the Investor by the Company.

 

(ii)       The
Company shall deliver to the Investor all Required Tranche Documents required to be delivered by it pursuant to Section 2.4(d)
of this Agreement at or prior to each Tranche Closing. Subject to such delivery and the satisfaction of the conditions set forth
in Section 2.4(c) as of the Tranche Closing Date, the closing of the purchase by the Investor of Tranche Shares shall occur
by 5:00 p.m. Eastern time, on the date which is five (5) Trading Days following (and not counting) the Tranche Notice Date (each
a “Tranche Closing Date”) at the offices of the Company. The initial Tranche Closing Date is referred to herein
as the “Initial Tranche Closing Date.”

 

(iii)       If
any portion of the Tranche Shares is converted by the Investor on or after the Tranche Notice Date and prior to or on the Tranche
Closing Date (which conversion shall be effected by Investor sending the conversion notice to the Company), the Company shall send
Investor an electronic copy of its share issuance instructions to the Transfer Agent and shall, if the restrictive legend prescribed
by Section 4.1 hereof is not required because of compliance with the provisions with that section, cause the requisite number
of shares of Common Stock to be credited to Investor’s account with DTC as DWAC Shares by 12:00 p.m. Eastern time on the
second Trading Day after the date the Company receives the conversion notice from Investor. If DWAC Shares are not timely credited
pursuant to this Section 2.4(e)(iii), then the Tranche Closing Date shall be extended by one (1) Trading Day for each Trading
Day that such timely credit of DWAC Shares is not made.

 

(iv)       The
closing (each, a “Tranche Closing”) for each Tranche shall occur on the date that both (i) the Company has delivered
to the Investor all Required Tranche Documents, and (ii) Investor has delivered to the Company the Tranche Purchase Price.

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

 

3.1          Representations and
Warranties of the Company. Except as set forth under the corresponding section of the Disclosure Schedules, which shall be
deemed a part hereof and which shall not contain any material non-public information, the Company hereby represents and warrants
to, and as applicable covenants with, Investor as of each Closing:

 

(a)       Corporate
Organization. The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware, and has full corporate power and authority to carry on its business as it is now being conducted and to own
the Properties it now owns, and (ii) is duly qualified or licensed to do business as a foreign corporation in good standing in
such other states in which it does business, except where such failure to be so qualified or licensed would not have a Material
Adverse Effect on the Company’s business; the Company is duly and properly registered pursuant to applicable state laws and
regulations in all states where the conduct of the Company’s business as presently conducted requires such registration.
The copies of the Certificate of Incorporation and Bylaws of the Company (the “Charter Documents”) annexed hereto
as Schedule 3.1(a) are complete and correct copies of such instruments as presently in effect.

 

    	 	 -8 - 	 

    	 

    

 

(b)       Authority.
The Company has the corporate power and the authority to execute, deliver and perform this Agreement and each other document contemplated
by this Agreement and the Transaction Documents. The execution, delivery and performance of the Transaction Documents by the Company
have been duly authorized by its board of directors. No other corporate proceedings on the part of the Company are necessary to
authorize the execution, delivery and performance of the Transaction Documents. The Transaction Documents have been duly executed
and delivered by the Company and, assuming due execution and delivery hereof by the Investor, are valid and legally binding agreements
of the Company, enforceable in accordance with their terms, subject to bankruptcy, insolvency, moratorium, reorganization and similar
laws of general applicability relating to or affecting creditors’ rights, to general equity principles, and public policy
considerations underlying the securities laws, to the extent that such public policy considerations limit the enforceability of
the provisions of the Transaction Documents that purport to provide indemnification for securities laws liabilities.

 

(c)       Capitalization.
Attached as Schedule 3.1(c) to this Agreement is a capitalization table setting forth the equity capitalization of the Company
as of the date hereof, and on a pro forma basis, after giving effect to the sale of the Shares.

 

Other than as set forth above
or on Schedule 3.1(c), no shares of capital stock or other voting or non-voting securities of the Company are issued, reserved
for issuance or outstanding. All outstanding shares of capital stock of the Company are duly authorized, validly issued, fully
paid and non-assessable and not subject to or issued in violation of any Purchase Right, right of first refusal, preemptive right,
subscription right or any similar right under any provision of the applicable corporate laws of the State of Delaware, the Charter
Documents, or any Contract to which the Company is a party or otherwise bound. Except as set forth on Schedule 3.1(c),
there are no oral and/or written, direct and/or indirect options, warrants, rights, convertible or exchangeable securities, “phantom”
stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of
any kind to which the Company is a party or by which it is bound; (a) obligating the Company to issue, deliver or sell, or cause
to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or
exercisable for or exchangeable into any capital stock of or other equity interest in, the Company, (b) obligating the Company
to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking
or (c) that give any Person the right to receive any economic benefit or right similar to or derived from the economic benefits
and rights occurring to holders of the capital stock of the Company. As of the date of this Agreement, there are no outstanding
contractual obligations of the Company to repurchase, redeem or otherwise acquire any shares of capital stock of the Company. To
the Company’s Knowledge, the offer and sale of all capital stock, convertible securities, rights, warrants, or options of
the Company issued prior to the Closing complied with all applicable federal and state securities laws and the Company has not
been notified by the Commission, the NYSE American, any state securities commission or any other Governmental Authority of the
absence of compliance by the Company with any federal and state securities laws or other Legal Requirements. No stockholder has
a matured and/or unmatured right of rescission or claim for damages with respect thereto.

 

(d)       Consents;
Permits; Defaults. Assuming the accuracy of the representations and warranties of the Investor in Section 3.2, other
than as contemplated in the Transaction Documents, none of the execution, delivery or performance of the Transaction Documents
by the Company, the consummation by the Investor of any transaction contemplated by the Transaction Documents, or compliance by
the Company with any of the provisions of the Transaction Documents will require (with or without notice or lapse of time, or both)
any consent, approval, authorization or permit of, or filing or registration with or notification to, any Governmental Authority
or any other Person, other than the failure to obtain such consents, approvals, authorizations or permits of, or to make such filings,
registrations with or notifications to any Governmental Authority or any other Person, individually or in the aggregate, has not
had a Material Adverse Effect on the Company.

 

(e)       Non-Contravention.
 The execution, delivery and performance the Transaction Documents by the Company does not and will not (i) result in a breach
of, or constitute a default under the Charter Documents, (ii) result in a breach of, or constitute a default under, any loan agreement,
indenture or mortgage or any material lease, agreement, franchise, license, permit or other undertaking or Contract to which the
Company is a party or any of its Properties may be subject or bound, (iii) result in a violation of any order, writ, injunction,
decree or award of any court or Governmental Authority including, but not limited to, the Commission, to the Company or relating
to any of its Properties, or (iv) result in a violation of any federal or state law, statute, ordinance, rule or regulation or
other Legal Requirement applicable the Company.

 

    	 	 -9 - 	 

    	 

    

 

(f)       Financial
Statements.

 

(i)       The
 Company has delivered or made available (for purposes of this section, filings that are publicly available prior to the date
hereof on the EDGAR system of the Commission under the name of the Company are deemed to have been made available) to the Investor:
(i) a true and complete copy of the Company’s unaudited consolidated balance sheet as of September 30, 2018 (the “Balance
Sheet Date”) and the related unaudited consolidated statements of operations, changes in the Company stockholder’s
deficit and cash flows for the period then ended and (ii) a true and complete copy of the Company’s audited balance sheet
as of December 31, 2017 and December 31, 2016 and the related audited statements of operations, changes in the Company stockholder’s
deficit and cash flows for each of the years ended December 31, 2017 and December 31, 2016, prepared in accordance with GAAP, together
with the report of Marcum, LLP, the Company’s independent registered public accounting firm (the “Firm”),
which has served as the Company’s auditors since the audit of its 2016 financial statements (such statements, including
the related notes and schedules thereto, are referred to herein as the “Financial Statements”). The Financial
Statements have been prepared from, are in accordance with, and accurately reflect, the books and records of the Company, comply
in all material respects with applicable accounting requirements in the case of the Financial Statements; fairly present in all
material respects the financial position and the results of operations and cash flows (and changes in financial position, if any)
of the Company as of the times and for the periods referred to therein (subject, in the case of unaudited statements, to normally
recurring year-end adjustments that are not material either individually or in the aggregate and the absence of footnotes). The
Financial Statements have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except
as set forth in the notes thereto). The Financial Statements are in form appropriate for filing with the Commission.

 

(ii)       The
Firm, which has certified the Company’s Financial Statements and related schedules, is an independent registered public accounting
firm with respect to the Company as required by the Securities Act and the rules and regulations promulgated thereunder and the
Public Company Accounting Oversight Board (United States).

 

(iii)      There
are no relationships or services, or any other factors that may affect the objectivity and independence of the Firm under applicable
auditing standards. The Firm has not performed any non-audit services for any Person related to the Company.

 

(g)       Contracts.

 

(i)   
    Schedule 3.1(g)(i) contains an accurate and complete list and terms of all the
Company’s Contracts. Other than as set forth on Schedule 3.1(g)(i) , the Company is not a party
to or bound by any of the following, whether written or oral:

 

(A)       Any
Contract that cannot by its terms be terminated by the Company with thirty (30) days’ or less notice without penalty or whose
term continues beyond one (1) year after the date of this Agreement;

 

(B)       Any
Contract or commitment for capital expenditures for non-product orders by the Company in excess of $100,000 per calendar quarter
in the aggregate other than purchase orders to vendors to manufacture products sold to customers;

 

(C)       Any
lease or license with respect to any material Properties, whether as landlord, tenant, licensor or licensee;

 

(D)       Any
Contract or other instrument relating to the borrowing of money or the guarantee of any obligation or the deferred payment of the
purchase price of any Properties;

 

(E)       Any
Contract with any Affiliate of the Company relating to the provision of goods or services by or to the Company other than purchase
orders to vendors to manufacture products sold to customers;

 

(F)       Any
Contract for the sale of any assets;

 

    	 	 -10 - 	 

    	 

    

 

(G)       Any
Contract that purports to limit the Company’s freedom to compete freely in any line of business or in any geographic area;

 

(H)       Any
preferential purchase right, right of first refusal, or similar agreement; or

 

(I)       Any
other Contract that is material to the business of the Company.

 

(ii)       All
of the Contracts listed or required to be listed in Schedule 3.1(g)(i) are valid, binding and to the Knowledge
of the Company, in full force and effect, and the Company has not been notified or advised by any party thereto of such party’s
intention or desire to terminate or modify any such Contract in any respect. To the Knowledge of the Company no other party is
in breach of any of the terms or covenants of any Contract listed or required to be listed on Schedule 3.1(g)(i)  that
has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Following the Closing,
the Company will continue to be entitled to all of the benefits currently held by the Company under each Contract listed or required
to be listed on Schedule 3.1(g)(i).

 

(iii)       The
Company is not a party to or bound by any Contract or Contracts the terms of which were arrived at by, or otherwise reflect, less-than-arm’s-length
negotiations or bargaining.

 

(h)       Absence
of Certain Changes or Events.

 

(i)       Except
as set forth on Schedule 3.1(h)(i), since the Balance Sheet Date, there has not been:

 

(A)       any
event, circumstance or change that had or would reasonably be expected to result in a Material Adverse Effect on the Company;

 

(B)       any
damage, destruction or loss (whether or not covered by insurance) that had or would reasonably be expected to result in a Material
Adverse Effect of the Company; or

 

(C)       any
Material Adverse Effect in the Company’s sales patterns, pricing policies, accounts receivable or accounts payable.

 

(ii)       Except
as set forth on Schedule 3.1(h)(ii), since the Balance Sheet Date, the Company has not:

 

(A)       merged
into or with or consolidated with, any other corporation or acquired the business or assets of any Person;

 

(B)       purchased
securities from any Person;

 

(C)       created,
incurred, assumed, guaranteed or otherwise become liable or obligated with respect to any Liabilities, or made any loan or advance
to, or any investment in, any person, except in each case in the ordinary course of business;

 

(D)       made
any change in any existing election, or made any new election, with respect to any tax law in any jurisdiction which election could
have an effect on the tax treatment of the Company or the Company’s business operations;

 

(E)       entered
into, amended or terminated a material Contract;

 

(F)       sold,
transferred, leased, mortgaged, encumbered or otherwise disposed of, or agreed to sell, transfer, lease, mortgage, encumber or
otherwise dispose of, any Properties;

 

    	 	 -11 - 	 

    	 

    

 

(G)       settled
any claim or litigation, or filed any motions, orders, briefs or settlement agreements in any proceeding before any Governmental
Authority or any arbitrator;

 

(H)       incurred
or approved, or entered into any Contract, agreement or commitment to make, any expenditures in excess of $100,000;

 

(I)       maintained
its Records and/or any other books of account other than in the usual, regular and ordinary manner in accordance with GAAP and
on a basis consistent with prior periods and has not made any change in any of its accounting methods or practices that would be
required to be disclosed under GAAP;

 

(J)       granted
any increase in the compensation payable or to become payable to directors, officers or employees (including, without limitation,
any such increase pursuant to any bonus, profit-sharing or other plan or commitment);

 

(K)       suffered
any extraordinary losses or waived any rights of material value;

 

(L)       made
any payment to any Affiliate or forgiven any indebtedness due or owing from any Affiliate to the Company other than director fees
and other payments described in the SEC Reports;

 

(M)       engaged
in any one or more activities or transactions with an Affiliate outside the ordinary course of business;

 

(N)       declared,
set aside or paid any dividends, or made any distributions or other payments in respect of its equity securities, or repurchased,
redeemed or otherwise acquired any such securities;

 

(O)       amended
its Charter Documents;

 

(P)       issued
any capital stock or other securities, or granted, or entered into any agreement to grant, any options, convertible rights, other
rights, warrants, calls or agreements relating to its capital stock; or

 

(Q)       agreed
or committed to do any of the foregoing.

 

(i)       Absence
of Undisclosed Liabilities and Agreements. The Company does not have any debt, loss, damage, adverse claim, liability or obligation
(whether direct or indirect, known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated
or unliquidated, or due or to become due, and whether in contract, tort, strict liability or otherwise) which are not accurately
reflected or provided for in the balance sheet dated as of the Balance Sheet Date included within the Financial Statements (whether
or not they are required to be disclosed under GAAP), other than (a) those incurred in the ordinary course of the Company’s
business since Balance Sheet Date, (b) those disclosed in this Agreement or the disclosure schedules and (c) those material obligations
arising subsequent to the date hereof pursuant to the express terms of executory Contracts, which executory Contracts (to the extent
such Contracts are material to the business of the Company) are identified on Schedule 3.1(i). Neither the Company
nor any of its officers or directors has effected any securitization transactions or “off-balance sheet arrangements”
(as defined in Item 303(c) of Regulations S-K of the Commission) since the Balance Sheet Date. Except as set forth on Schedule 3.1(i) or
otherwise contemplated by this Agreement, as of the Closing there will be no Liabilities of the Company.

 

(j)       Compliance
with Law. The business of the Company has been operated in compliance with all Legal Requirements, including all laws, ordinances,
rules, regulations and orders of all Governmental Authorities and the NYSE American, except where such failure would not have a
Material Adverse Effect on the Company or its business. The Company has filed all reports and statements, including but not limited
to the SEC Reports, together with any amendments required to be made with respect thereto, that it was required to file with any
Governmental Authority or any other body having jurisdiction over the Company’s operations. The Company has not received
any written communication from a Governmental Authority that alleges that the Company is not in compliance with any federal, state,
local or foreign laws, ordinances and regulations or has not made all of the filings required by all such authorities, organizations
and agencies.

 

    	 	 -12 - 	 

    	 

    

 

(k)       Tax
Matters. All Tax Returns required to be filed by or on behalf of the Company have been duly and timely filed with the appropriate
Taxing Authority in all jurisdictions in which such Tax Returns are required to be filed (after giving effect to any valid extensions
of time in which to make such filings), and all such Tax Returns are true, complete and correct in all material respects. All Taxes
payable by or on behalf of the Company (whether or not shown on any Tax Return) have been fully and timely paid. With respect to
any period for which Tax Returns have not yet been filed or for which Taxes are not yet due or owing, the Company has made due
and sufficient accruals for such Taxes in the Financial Statements and in its books and records. All required estimated Tax payments
sufficient to avoid any underpayment penalties or interest have been made by or on behalf of the Company. The Company has complied
in all material respects with all applicable laws relating to the payment and withholding of Taxes in connection with amounts paid
or owing to any employee, independent contractor, creditor, equity owner or other third party and has duly and timely withheld
and paid over to the appropriate Taxing Authority all amounts required to be so withheld and paid under all applicable laws.

 

(l)       Absence
of Questionable Payments. Neither the Company nor any Affiliate, director, officer, partner, employee, agent, representative
or other Person acting on behalf of the Company has: (i) used any funds for contributions, payments, gifts or entertainment, or
made any expenditures relating to political activities of foreign, federal, state or local government officials or others in violation
of any law (including the Foreign Corrupt Practices Act of 1977, as amended), or (ii) accepted or received any unlawful contributions,
payments, gifts or expenditures.

 

(m)       Litigation.
Other than as set forth on Schedule 3.1(m), there is no claim, action, suit or proceeding pending or, to the Knowledge of
the Company, threatened against any of the Company or its Properties which, if adversely determined, will affect or can reasonably
be expected to affect materially and adversely, the Company, or which seeks to prohibit, restrict or delay consummation of the
transaction contemplated hereby or any of the conditions to consummation of such transaction, nor to the Knowledge of the Company
is there any judgment, decree, injunction, ruling or order of any court, Governmental Authority, including, but not limited to,
the Commission, any commission, agency or instrumentality or arbitrator outstanding against the Company having, or which may in
the future have, any such effect. Neither the Company nor any Affiliate thereof is under investigation with respect to, any violation
of any provision of any federal or state law or administrative regulation in respect of the business of the Company. The Company
is not a party to or bound by any judgment, decree, injunction, ruling or order of any Governmental Authority or any other person
which has affected or may affect materially and adversely the Preferred Shares.

 

(n)       Title
to Property.

 

(i)       
Personal Property. All material items of personal property used in the business of the Company are in good operating condition
and fit for operation in the ordinary course of the Company’s business (subject to normal wear and tear) with no defects
that could reasonably be expected to interfere with the conduct of the normal operation of such items and are suitable for the
purposes for which they are currently being used.

 

(ii)       Real
Property. The Company owns no real property. The Company’s only leased properties are the properties in Newport Beach,
CA, Fremont, CA, Israel and Salisbury, the United Kingdom (collectively, the “Leased Properties”). All real
estate Taxes for which the Company is responsible with respect to any Leased Property (and which are not otherwise incorporated
into payments made under any lease), have been paid in full, as and when due.

 

(o)       Intellectual
Property. The Company has, or has rights to use, all Intellectual Property necessary for the conduct of the business of the
Company as currently conducted. The Company has received no written notice that the Intellectual Property used by it violates or
infringes upon the rights of any Person. All rights to such Intellectual Property are enforceable and to the Knowledge of the Company,
there is no existing infringement by another Person of any of the rights to the Company’s Intellectual Property of others.
All the Company’s Intellectual Property rights registered or applied for registration under the name of the Company are set
forth on Schedule 3.1(o).

 

    	 	 -13 - 	 

    	 

    

 

(p)       SEC
Reports. The Company has filed with the Commission all SEC Reports required to be filed pursuant to the Securities Act and
Exchange Act and is current in its reporting obligations. As of their respective dates, all SEC Reports complied in all material
respects with requirements of the Securities Act and Exchange Act and the rules and regulations promulgated thereunder and none
of the SEC Reports when they were filed contained an untrue statement of a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(q)       Books
and Records; Internal Accounting Controls. The Records of the Company accurately reflect in all material respects the information
relating to the business of the Company, the location and collection of its Properties and the nature of all transactions giving
rise to the obligations or accounts receivable of the Company to the extent required to be contained therein. The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate actions is taken with respect to any differences.

 

(r)       Broker.
The Company has not retained any broker in connection with any transaction contemplated by this Agreement. The Company shall not
be obligated to pay any fee or commission associated with the retention or engagement by the Company of any broker in connection
with any transaction contemplated by this Agreement.

 

(s)       Common
Stock Symbol. The Company Common Stock is currently listed on the NYSE American under the symbol “DPW.”

 

(t)       No
Commission or NYSE American Inquiries; Delisting. Except as set forth on Schedule 3.1(t), to the best of the Company’s
Knowledge, the Company is not, and has never been, the subject of any formal or informal inquiry or investigation by the Commission
or the NYSE American. Except as set forth on Schedule 3.1(t), the Company has no Knowledge of any action by the
Commission or the NYSE American that seeks to deregister or delist the Common Stock from the NYSE American or otherwise render
such shares ineligible for listing and trading on the NYSE American.

 

(u)       Preferred
Shares. The Preferred Shares and the Conversion Shares will, upon each issuance whether pursuant to Tranche Notice or conversion
of the Preferred Shares, be duly authorized, fully paid and non-assessable and vest in the holder thereof title thereto free and
clear of any restrictions on transfer (other than any restrictions under applicable state or federal securities laws), Taxes, Encumbrances,
options, warrants, Purchase Rights, Contracts, commitments, equities, claims, and demands and will not be subject to any pre-emptive
or other similar rights.

 

(v)       Disclosure
of Material Information. Neither the Company nor any other Person acting on its behalf has provided or will provide the Investor
or its agents or counsel with any information that the Company believes constitutes material non-public information (other than
with respect to the transactions contemplated by this Agreement and the Transaction Documents). The Company understands and confirms
that the Investor will be relying on the foregoing representations in effecting transactions in the Preferred Shares.

 

(w)       Labor
Matters. The Company is not a party to any representation or collective bargaining agreement with any employees.

 

(x)       Employment
Agreements and Plans.  The Company has furnished the Investor with a list of all employment, consulting, advisory and
confidentiality agreements to which the Company is a party. The Company has delivered to the Investor true and complete copies
of each such agreement (or written descriptions thereof for any such agreements which are not in writing). Except as set forth
on Schedule 3.1(x), the Company has not and does not maintain or contribute to any outstanding incentive compensation,
deferred compensation, profit sharing, stock option, stock bonus, stock purchase, savings, consultant, retirement, pension, medical,
dental, disability or other benefit plans or arrangements with or for the benefit of any officer, employee or former officer, employee
of the Company or for the benefit of any distributor, sales representative or other person resulting from a relationship with the
Company.

 

    	 	 -14 - 	 

    	 

    

 

(y)       Insurance.
The Company has furnished the Investor with a list of all material bonds and liability, fire and other insurance contracts of whatsoever
description to which the Company is a party, and under which the Company is or was a beneficiary.

 

(z)       Director
and Officer Insurance. The Company has maintained insurance for its officers and directors for the last five (5) years without
any lapse in coverage.

 

(aa)     DTC Eligibility.
The Company’s Transfer Agent is a participant in and the Common Stock is eligible for transfer pursuant to the Depository
Trust Company’ Fast Automated Securities Transfer Program.

 

(bb) 
  Disclosure. No representation or warranty by the Company in this Agreement, the Exhibits or the
Schedules hereto and thereto and no statement contained in any document, certificate, or other writing furnished or to be
furnished by the Company to the Investor or any of its representatives or agents pursuant to the provisions hereof or in
connection with the transactions, contains or will contain any untrue statement of material fact or omits or will omit to
state any material fact necessary in order to make the statements herein or therein made, in the light of the circumstances
under which they were made, not misleading.

 

3.2          Representations
and Warranties of Investor. Investor hereby represents and warrants as of the Effective Date as follows:

 

(a)       Authority.
The Investor has all necessary corporate power and authority to execute and deliver the Transaction Documents, to perform its obligations
hereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and
the Transaction Documents by the Investor, and the consummation by the Investor of the transactions contemplated hereby have been
duly and validly authorized by its board of directors, and no other corporate proceedings on the part of the Investor are necessary
to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement and the Transaction Documents
have been duly validly executed and delivered by the Investor and, assuming due authorization, execution and delivery by the Company,
constitutes a legally valid and binding obligation of the Investor, enforceable against the Investor in accordance with its terms
(except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and other similar laws affecting creditors’ rights generally and subject to the effect of general principles of equity, whether
considered in a proceeding in equity or at law).

 

(b)       No
Conflict. None of the execution, delivery or performance of the Transaction Documents by the Investor, the consummation by
the Investor of the transactions contemplated by this Agreement, or compliance by the Investor with any of the provisions of this
Agreement will (with or without notice or lapse of time, or both): (a) conflict with or violate any provision of the organizational
or governing documents of the Investor, or (b) assuming that all consents, approvals, authorizations and permits described in Section
3.1(d) have been obtained and all filings and notifications described in Section 3.1(d) have been made and any waiting
periods thereunder have terminated or expired, conflict with or violate any law applicable to the Investor, except, with respect
to clause (b), for any such conflicts, violations, consents, breaches, losses, defaults, other occurrences which, individually
or in the aggregate, have not had a Material Adverse Effect on the Investor.

 

(c)       Information
in the Form 8-K. The information supplied by the Investor in writing expressly for inclusion or incorporation by reference
in the Form 8-K (as hereinafter defined) and any amendment thereof or supplement thereto, will not, on the date submitted to the
Company, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
in order to make the statements made therein, in light of the circumstances under which they are made, not misleading.

 

    	 	 -15 - 	 

    	 

    

 

(d)       Securities
Act Representations.

 

(i)       Restricted
Shares. The Investor represents that it understands that the Preferred Shares to be sold to it pursuant to this Agreement will
not be registered pursuant to the registration requirements of the Securities Act and that the resale of such Preferred Shares
is subject to certain restrictions hereunder and under federal and state securities laws. The Investor represents that it is acquiring
such Preferred Shares for its own account, not as a nominee or agent, and not with a view to the distribution thereof in violation
of applicable securities laws. The Investor further represents that it has been advised and understands that since such Preferred
Shares have not been registered under the Securities Act, such Preferred Shares must be held indefinitely unless (A) the resale
of such Preferred Shares has been registered under the Securities Act, (B) a sale of such Preferred Shares is made in conformity
with the holding period, volume and other limitations of Rule 144 promulgated by the Commission under the Securities Act, or (C)
in the opinion of counsel reasonably acceptable to the Company, some other exemption from registration is available with respect
to any proposed sale, transfer or other disposition of such Preferred Shares.

 

(ii)       Legend.
The Investor represents that it has been advised and understands that, subject to applicable securities laws, stop transfer instructions
will be given to the Company’s Transfer Agent with respect to the Preferred Shares and shares of Common Stock issuable upon
conversion thereof and that a legend, substantially in the form provided for in Section 4.1(b), setting forth the restrictions
on transfer will be set forth on the certificates for the Preferred Shares or any substitutions therefor.

 

(iii)       Accredited
Investor. The Investor is an “accredited investor” (as such term is defined in Regulation D under the Securities
Act).

 

(iv)       Litigation.
There are no actions, suits, arbitrations, mediations, proceedings or claims pending or, to the knowledge of the Investor, threatened
against Investor that seek to restrain or enjoin the consummation of the transactions contemplated hereby.

 

(v)       Acknowledgement
of Receipt of Information. The Investor has had an opportunity to ask questions and receive answers and materials, and to discuss
the business of the Company and its Subsidiaries and related matters, with certain key officers of the Company and its Subsidiaries
regarding the transactions contemplated hereunder (the “Investigation”). The Investor hereby acknowledges and
agrees that other than the Company’s representations and warranties set forth in Section 3.1, neither the Company
nor any of its representatives makes or has made any representation or warranty, express or implied, at law or in equity, with
respect to the business of the Company or any Subsidiary thereof nor with respect to the Preferred Shares. Nothing in this Section
3.2(d)(v) (including any information provided to the Investor by the Company pursuant to the Investigation) shall derogate
from the representations and warranties of the Company contained in Section 3.1 hereof or from the ability of Investor to
rely on such representations and warranties or to seek indemnification for Losses in respect of such representations and warranties.

 

ARTICLE 4

OTHER AGREEMENTS OF THE PARTIES

 

4.1          Transfer
Restrictions

 

(a)       The
Preferred Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Preferred Shares other than (i) pursuant to an effective Registration Statement or Rule 144, (ii) to the Company, (iii) to an
Affiliate of Investor, or (iv) in connection with a pledge as contemplated in Section 4.1(b), the Company may require the
transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the
Company, to the effect that such transfer does not require registration of such transferred Preferred Shares under the Securities
Act.

 

    	 	 -16 - 	 

    	 

    

 

(b)       Investor
agrees to the imprinting, so long as is required by this Section 4.1 of the following legend, or substantially similar legend,
on any certificate evidencing Preferred Shares that qualify to have the legend removed as provided below:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR
SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

The Company agrees to cause
such legend to be removed immediately upon effectiveness of a Registration Statement, or when any securities are eligible for sale
under Rule 144 and, if requested by Investor or the Transfer Agent, to promptly provide at the Company’s expense a legal
opinion of counsel to the Company confirming that such legend may be removed. Company further acknowledges and agrees that Investor
may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest
in some or all of the Preferred Shares to a financial institution that is an “accredited investor” as defined in Rule
501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under the terms
of such arrangement, Investor may transfer pledged or secured Preferred Shares to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party
or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At Investor’s
reasonable expense, the Company will execute and deliver such documentation as a pledgee or secured party of Preferred Shares may
reasonably request in connection with a pledge or transfer of the Preferred Shares.

 

4.2          Furnishing of Information.
As long as Investor owns Preferred Shares, the Company covenants to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be filed by the Company after the Effective Date pursuant to the Exchange
Act. Upon the request of Investor, the Company shall deliver to Investor a written certification of a duly authorized officer as
to whether it has complied with the preceding sentence. As long as Investor owns Preferred Shares, if the Company is not required
to file reports pursuant to such laws, it will prepare and furnish to Investor and make publicly available in accordance with Rule
144(c) such information as is required for Investor to sell the Preferred Shares under Rule 144. The Company further covenants
that it will take such further action as any holder of Preferred Shares may reasonably request, all to the extent required from
time to time to enable such Person to sell such Preferred Shares without registration under the Securities Act within the limitation
of the exemptions provided by Rule 144. 

 

4.3          Integration. The
Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Preferred Shares in a manner that would
require the registration under the Securities Act of the sale of the Preferred Shares to Investor or that would be integrated with
the offer or sale of the Preferred Shares for purposes of the rules and regulations of any Trading Market such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing
of such subsequent transaction. 

 

4.4          Securities
Laws Disclosure; Publicity. The Company shall timely file a Current Report on Form 8-K as required by this Agreement, and shall
file a press release, in each case reasonably acceptable to Investor, disclosing the material terms of the transactions contemplated
hereby. The Company and Investor shall consult with each other in issuing any press releases with respect to the transactions contemplated
hereby, and neither the Company nor Investor shall issue any such press release or otherwise make any such public statement without
the prior consent of the Company, with respect to any such press release of Investor, or without the prior consent of Investor,
with respect to any such press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such
disclosure is required by law or Trading Market regulations, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly
disclose the name of Investor, or include the name of Investor in any filing with the Commission or any regulatory agency or Trading
Market, without the prior written consent of Investor, except (i) as contained in the Current Report on Form 8-K and press release
described above, (ii) as required by federal securities law in connection with any registration statement under which the securities
are registered, (iii) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company
shall provide Investor with prior notice of such disclosure, or (iv) to the extent such disclosure is required in any SEC Report
filed by the Company.

 

    	 	 -17 - 	 

    	 

    

 

4.5          Shareholders
Rights Plan. No claim will be made or enforced by the Company or, to the Knowledge of the Company, any other Person that Investor
is an “Acquiring Person” under any shareholders rights plan or similar plan or arrangement in effect or hereafter adopted
by the Company, or that Investor could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Preferred Shares under the Transaction Documents or under any other agreement between the Company and Investor. The Company shall
conduct its business in a manner so that it will not become subject to the Investment Company Act of 1940, as amended. 

 

4.6          Non-Public
Information. The Company covenants and agrees that neither it nor any other Person acting on its behalf will provide Investor
or its agents or counsel with any information that the Company believes or reasonably should believe constitutes material non-public
information, unless prior thereto Investor shall have executed a written agreement regarding the confidentiality and use of such
information. On and after the Effective Date, neither Investor nor any Affiliate Investor shall have any duty of trust or confidence
that is owed directly, indirectly, or derivatively, to the Company or the shareholders of the Company, or to any other Person who
is the source of material non-public information regarding the Company. The Company understands and confirms that Investor shall
be relying on the foregoing in effecting transactions in securities of the Company.

 

4.7          Reimbursement.
If Investor becomes involved in any capacity in any proceeding by or against any Person who is a stockholder of the Company
(except as a result of sales, pledges, margin sales and similar transactions by Investor to or with any current stockholder), solely
as a result of Investor’s acquisition of the Preferred Shares under this Agreement, the Company will reimburse Investor for
its reasonable legal and other expenses (including the cost of any investigation preparation and travel in connection therewith)
incurred in connection therewith, as such expenses are incurred, or will assume the defense of Investor in such matter. The reimbursement
obligations of the Company under this Section 4.7 shall be in addition to any liability which the Company may otherwise
have, shall extend upon the same terms and conditions to any Affiliates of Investor who are actually named in such action, proceeding
or investigation, and partners, directors, agents, employees and controlling persons (if any), as the case may be, of Investor
and any such Affiliate, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives
of the Company, Investor and any such Affiliate and any such Person. The Company also agrees that neither Investor nor any such
Affiliates, partners, directors, agents, employees or Controlling Persons shall have any liability to the Company or any Person
asserting claims on behalf of or in right of the Company solely as a result of acquiring the Preferred Shares under this Agreement. 

 

4.8          Indemnification
of Investor

 

(a)       Company
Indemnification Obligation. Subject to the provisions of this Section 4.8, the Company will indemnify and hold Investor,
its Affiliates and attorneys, and each of their directors, officers, shareholders, partners, employees, agents, and any person
who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively,
the “Investor Parties” and each an “Investor Party”), harmless from any and all Losses that
any Investor Party may suffer or incur as a result of or relating to (i) any breach of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, or (ii) any action instituted
against any Investor Party, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate
of an Investor Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is
based upon a breach of Investor’s representations, warranties or covenants under the Transaction Documents or any agreements
or understandings Investor may have with any such stockholder or any violations by Investor of state or federal securities laws
or any conduct by Investor which constitutes fraud, gross negligence, willful misconduct or malfeasance), (iii) any untrue statement
or alleged untrue statement of a material fact contained in a Registration Statement (or in a Registration Statement as amended
by any post-effective amendment thereof by the Company) or arising out of or based upon any omission or alleged omission to state
a material fact required to be stated therein or necessary to make the statements therein not misleading, and/or (iv) any untrue
statement or alleged untrue statement of a material fact included in any Prospectus (or any amendments or supplements to any Prospectus),
in any free writing prospectus, in any “issuer information” (as defined in Rule 433 under the Securities Act) of the
Company, or in any Prospectus together with any combination of one or more of the free writing prospectuses, if any, or arising
out of or based upon any omission or alleged omission to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading.

 

    	 	 -18 - 	 

    	 

    

 

(b)       Indemnification
Procedures. If any action shall be brought against an Investor Party in respect of which indemnity may be sought pursuant to
this Agreement, such Investor Party shall promptly notify the Company in writing, and the Company shall have the right to assume
the defense thereof with counsel of its own choosing. The Investor Parties shall have the right to employ separate counsel in any
such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Investor
Parties except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the
Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of such separate counsel, a material conflict with respect to the dispute in question on any material
issue between the position of the Company and the position of the Investor Parties such that it would be inappropriate for one
counsel to represent the Company and the Investor Parties. The Company will not be liable to the Investor Parties under this Agreement
(i) for any settlement by an Investor Party effected without the Company’s prior written consent, which shall not be unreasonably
withheld or delayed; or (ii) to the extent, but only to the extent that a loss, claim, damage or liability is either attributable
to Investor’s breach of any of the representations, warranties, covenants or agreements made by Investor in this Agreement
or in the other Transaction Documents.

 

4.9          Required
Approval. Other than Required Approval of the NYSE American, no transactions contemplated under this Agreement or the Transaction
Documents shall be consummated for an amount that would require any other approval by any Trading Market or Company stockholders.

 

ARTICLE 5

TERMINATION

 

5.1          Termination. The
Investor may elect to terminate this Agreement (a “Termination”) upon the occurrence of any of the following:(a)

 

(b)       if,
at any time, either the Company or any director or executive officer (excluding any director or executive officer who is a manager,
member or affiliate of Investor) of the Company has engaged in a transaction or conduct related to the Company that has resulted
in (i) an SEC enforcement action, including without limitation such director or executive officer being sanctioned by the Commission,
or (ii) a civil judgment or criminal conviction for fraud or misrepresentation, or for any other offense that, if prosecuted criminally,
would constitute a felony under applicable law;

 

(c)       on
any date after a Delisting Period that lasts for an aggregate of twenty (20) Trading Days during any calendar year;

 

(d)       if
at any time the Company has filed for and/or is subject to any bankruptcy, insolvency, reorganization or liquidation proceedings
or other proceedings for relief under any bankruptcy law or any law for the relief of debtors instituted by or against the Company
or any Subsidiary of the Company;

 

(e)       the
Company is in breach or default of any Material Agreement, which breach or default could have a Material Adverse Effect;

 

(f)       the
Company is in breach or default of this Agreement, any Transaction Document, or any agreement with Investor or any Affiliate of
Investor;

 

(g)       upon
the occurrence of a Fundamental Transaction;

 

(h)       so
long as any Preferred Shares are outstanding, the Company effects or publicly announces its intention to create a security senior
to the Series C Preferred Stock, or substantially altering the capital structure of the Company in a manner that, in the Investor’s
opinion, materially adversely affects the rights or preferences of the Series C Preferred Stock; or

 

    	 	 -19 - 	 

    	 

    

 

(i)       on
the Termination Date.

 

5.2          Effect
of Termination. Except as otherwise provided herein, the termination of this Agreement will have no effect on any Preferred
Shares or DWAC Shares previously issued, delivered or credited, or on any then-existing rights of any holder thereof.

 

ARTICLE 6

MISCELLANEOUS

 

6.1          Fees
and Expenses. Each party shall pay the fees and expenses of its own advisers, counsel, accountants and other experts, if any,
and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of
the Transaction Documents. The Company shall pay all stamp and other taxes and duties levied in connection with the sale of the
Preferred Shares, if any.

 

6.2          Notices.
Unless a different time of day or method of delivery is set forth in the Transaction Documents, any and all notices or other communications
or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the
earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or electronic mail prior
to 5:30 p.m. Eastern time on a Trading Day and an electronic confirmation of delivery is received by the sender, (b) the next Trading
Day after the date of transmission, if such notice or communication is delivered later than 5:30 p.m. Eastern time or on a day
that is not a Trading Day, (c) three (3) Trading Days following the date of mailing, if sent by U.S. nationally recognized overnight
courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The addresses for such notices
and communications are those set forth following the signature page hereof, or such other address as may be designated in writing
hereafter, in the same manner, by such Person.

 

6.3          Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by the Company and Investor or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No
waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

6.4          Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

6.5          Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
Investor, which consent shall not be unreasonably withheld or delayed. Investor may assign any or all of its rights under this
Agreement (a) to any Affiliate, or (b) to any Person to whom Investor assigns or transfers any Preferred Shares.

 

6.6          No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.8.

 

6.7          Governing
Law; Dispute Resolution. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the laws of the State of New York, without regard
to the principles of conflicts of law that would require or permit the application of the laws of any other jurisdiction. Each
party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated
by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the
City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action
or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall
be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses reasonably incurred in connection
with the investigation, preparation and prosecution of such action or proceeding.

 

    	 	 -20 - 	 

    	 

    

 

6.8          Survival.
The representations and warranties contained herein shall survive the Closing and the delivery and conversions of the Preferred
Shares.

 

6.9          Execution.
This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it
being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or in a PDF by e-mail transmission, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original
thereof.

 

6.10          Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will
attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

6.11          Replacement
of Preferred Shares. If any certificate or instrument evidencing any Preferred Shares is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and
substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or
instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement
Preferred Shares.

 

6.12          Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each
of Investor and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at
law would be adequate. Neither the Company nor Investor shall be liable for special, indirect, consequential or punitive damages
suffered or alleged to be suffered by the other party or any third party, whether arising from or related to the Transaction Documents
or otherwise.

 

6.13          Payment
Set Aside. To the extent that the Company makes a payment or payments to Investor pursuant to any Transaction Document or Investor
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any
part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the
extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.14          Time
of the Essence. Time is of the essence with respect to all provisions of this Agreement that specify a time for performance.

 

    	 	 -21 - 	 

    	 

    

 

6.15          Construction.
The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto. The language used in this
Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction
will be applied against any party.

 

6.16          Entire
Agreement. This Agreement, together with the Exhibits, Appendices and Schedules hereto, contains the entire agreement and understanding
of the parties, and supersedes all prior and contemporaneous agreements, term sheets, letters, discussions, communications and
understandings, both oral and written, which the parties acknowledge have been merged into this Agreement. No party, representative,
attorney or agent has relied upon any collateral contract, agreement, assurance, promise, understanding or representation not expressly
set forth hereinabove. The parties hereby expressly waive all rights and remedies, at law and in equity, directly or indirectly
arising out of or relating to, or which may arise as a result of, any Person’s reliance on any such assurance.

 

    	 	 -22 - 	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

 

	DPW HOLDINGS, INC.	 
	 	 	 
	 	 	 
	By: 	 	 
	Name: 	William B. Horne	 
	Title:	Chief Financial Officer	 
	 	 	 
	 	 	 
	 	 	 
	AULT & COMPANY, INC.	 
	 	 	 
	 	 	 
	By: 	 	 
	Name: 	Milton C. Ault, III	 
	Title:	Chief Executive Officer	 

 

    	 	 	 

    	 

    

 

Addresses for Notice

 

 

To Company:

 

DPW Holdings, Inc.

201 Shipyard Way

Newport Beach, California 92663

Attention: William Horne, Chief Horne Officer

 

Telephone: (949) 444-5464

Facsimile:

Email: Will@dpwholdings.com

 

with a copy (which shall not constitute notice) to:

 

Sichenzia Ross Ference LLP

1185 Avenue of the Americas, 37th Floor

New York, New York 10036

Attention: Marc J. Ross, Esq.

 

Telephone: (212) 930-9700

Facsimile: (212) 930- 9725

Email: mross@srf.law

 

To Investor:

 

_____________

_____________

_____________

 

Telephone:

Facsimile:

Email:cbay-ex1016_257.htm

Exhibit 10.16

 

September 4, 2018

 

Klara Dickinson 

c/o CymaBay Therapeutics, Inc.

7999 Gateway Blvd., Suite 130 

Newark, CA 94560

Dear Klara:

CymaBay Therapeutics, Inc. (the “Company”) is pleased to continue your employment as Senior Vice President, Regulatory Affairs and Quality Assurance on the following terms:

1.Position, Duties and Responsibilities.  Subject to the terms set forth herein, the Company agrees to employ you in the position of Senior Vice President, Regulatory Affairs and Quality Assurance and you hereby accept such employment effective immediately. You will report to the Company’s Chief Executive Officer (the “CEO”) and will perform such duties as are assigned to you by the CEO.  You will devote your full business time and attention to the business affairs of the Company, except for reasonable vacations and periods of illness or incapacity permitted by the Company’s general employment policies.  The employment relationship between you and the Company shall also be governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this letter agreement differ from, or are in conflict with, the Company’s general employment policies or practices, this letter agreement shall control.  Subject to the other terms of this letter agreement, the Company may change your position, duties, reporting relationship and work location from time to time in its discretion.

2.Compensation and Employee Benefits.

2.1Base Salary.  Your base salary will be three hundred forty thousand two hundred four dollars ($340,204) on an annualized basis, less payroll deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. Subject to the other terms of this letter agreement, your base salary may be modified by the Company in its sole discretion. 

2.2Discretionary Bonus.  You will be eligible to participate in the Company’s annual bonus program pursuant to the terms of that program and you will be eligible to receive a bonus of up to thirty-five percent (35%) of your annual base salary. Your actual bonus, if any, will be determined by the Company’s Board of Directors (the “Board”), or the Compensation subcommittee thereof, in its sole discretion, based upon its evaluation of your performance, the Company’s performance, and any other considerations it deems relevant.  You 

1.

 

 

 

must be employed through the bonus payment date to be eligible for, and to earn, any such bonus.  Bonuses are typically paid within sixty (60) days after the end of the calendar year.  Any bonus payment will be subject to payroll deductions and required withholdings.

2.3Employee Benefits.  You will be entitled to all employee benefits, including vacation accrual of twenty (20) days per year and health and disability benefits for which you are eligible under the terms and conditions of the standard Company benefit plans that may be in effect from time to time and provided by the Company to its senior executive-level employees generally.  Currently, such benefits include thirteen (13) paid holiday days, as well as paid sick leave of up to ten (10) days per year. Notwithstanding the foregoing, the Company reserves the right to adopt, amend or discontinue any employee benefit plan or policy, including changes required by applicable law.

2.4Equity Awards.  Subject to the approval of the Board, or the Board’s Compensation Committee, pursuant to the Company’s equity incentive plan, you may from time to time be granted equity awards.  Such equity awards will vest as provided by the applicable award agreements as long as you remain in continuous service with the Company and may vest on an accelerated basis pursuant to Articles 6 or 7.  Except as provided herein, such equity awards will be subject to the provisions of the equity incentive plan of the Company under which the applicable equity award is granted and the applicable form of equity award agreement thereunder (the “Plan Documents”).

3.Other Activities During Employment.

3.1Activities.  Except with the prior written consent of the CEO, you will not, during your employment with the Company, undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of your job duties for the Company.

3.2Investments and Interests.  Except as permitted by the first sentence of Section 3.1 and by Section 3.3, during your employment you agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company, or its business or prospects, financial or otherwise.

3.3Noncompetition.  During the term of your employment by the Company, except on behalf of the Company, you will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company; provided, however, that anything above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate constitute more than one percent (1%) of the voting stock of such corporation.

2.

 

 

 

4.Company Policies; Confidential Information and Inventions Agreement.  You acknowledge your obligations under your Company Employee Agreement on Confidential Information and Inventions.  You further acknowledge your obligation to abide by the Company’s rules, policies and procedures.

5.Your Representations and Warranties.

5.1No Breach of Contract.  You represent and warrant that the execution and delivery of this letter agreement by you and the performance of your obligations hereunder will not conflict with or breach any agreement, order or decree to which you are a party or by which you are bound.  You warrant that you are subject to no employment agreement or restrictive covenant preventing full performance of your duties under this letter agreement.

5.2No Conflict of Interest.  You warrant that you are not, to the best of your knowledge and belief, involved in any situation that might create, or appear to create, a conflict of interest with your loyalty to or duties for the Company.

5.3Notification of Materials or Documents from Other Employers.  You further warrant that you have not brought and will not bring to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former employer for their possession and use.

5.4Notification of Other Post-Employment Obligations.  You also understand that, as part of your employment with the Company, you are not to breach any obligation of confidentiality that you have to former employers, and you agree to honor all such obligations to former employers during your employment with the Company.

6.Termination of Employment.

6.1At-Will Employment Relationship.  Your employment with the Company shall be at-will. Either you or the Company may terminate the employment relationship at any time, with or without Cause, and with or without advance notice.

6.2Termination for Cause.

(a)Subject to the terms of this Article 6 and to the terms of Article 7, if the Company terminates your employment at any time for Cause (as defined below), your salary shall cease on the date of termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required by applicable law or the terms of applicable benefit plans. Subject to the terms of this Article 6 and to the terms of Article 7, the continued vesting of any equity awards held by you shall cease on your employment termination date, and your right to exercise vested equity awards shall be governed by the Plan Documents.

(b)Definition of Cause.  For purposes of this letter agreement, “Cause” means the occurrence of any one or more of the following: (i) your conviction of, or 

3.

 

 

 

plea of no contest, with respect to any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) your participation in a fraud or act of dishonesty that results in material harm to the Company; (iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited to this letter agreement or your Employee Agreement on Confidential Information and Inventions, or your violation of any statutory duty that you owe to the Company, but only if you do not correct any such violation within thirty (30) days after written notice thereof has been provided to you (if such notice is reasonably practicable); or (iv) your gross negligence or willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after written notice thereof has been provided to you (if such notice is reasonably practicable).

6.3Severance Benefits for Termination Without Cause or Resignation for Good Reason.

(a)If the Company terminates your employment without Cause and other than as a result of your death or disability, or if you resign your employment for Good Reason (defined below), and provided such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), you will be eligible to receive the severance benefits described in this Section 6.3. 

(b)You will be eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation for twelve (12) months of the greater of your base salary: (i) in effect as of such termination date; or (ii) as set forth in Section 2.1.  In addition, you will be eligible to receive your annual discretionary bonus amount at the higher of that (a) in effect as of such termination date; or (b) as set forth in Section 2.2, in either case determined as if all performance targets have been satisfied, pro-rated for the number of months elapsed in the year in which your employment terminates, but in no event will you receive a bonus pro-rated for less than nine (9) months.  You agree to notify the Company promptly of any amount earned by you from other employment or a consulting engagement while you are receiving severance payments under this letter agreement.

(c)If you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following your Separation from Service, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period.  You agree to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the 60th day following your Separation from Service, the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above.  If you become eligible for coverage under another employer's group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must 

4.

 

 

 

immediately notify the Company of such event, and all payments and obligations under this clause will cease.

(d)You will receive acceleration of vesting of all of your then-outstanding and then-unvested equity award grants as of the date of termination as to the number of shares that would have vested in their vesting schedules as if you had been in service for an additional twelve (12) months as of your Separation from Service.  

(e)Your receipt of any severance benefits under this Section 6.3 is contingent upon your signing and making effective within sixty (60) days after the termination date, a full, general release of all claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit A on or after the termination date. The base salary and bonus severance will be paid in substantially equal installments over the twelve (12) month period following your Separation in Service according to the Company’s payroll procedures; provided, however, that no payments will be made to you prior to the 60th day following your Separation from Service. On the first payroll pay day following the 60th day after your Separation from Service, the Company will pay you the cash severance amounts you would have received on or prior to such date in a lump sum in compliance with Code Section 409A and the effectiveness of the release, with the balance of the cash payments being made as originally scheduled.

(f)Definition of Good Reason.  For purposes of this letter agreement, “Good Reason” shall mean any one of the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not merely a change in reporting relationships); (ii) a material reduction in your level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs); (iii) a material change of your place of employment that results in an increase to your round trip commute of more than twenty (20) miles; or (iv) the Company’s material breach of this letter agreement. Notwithstanding the foregoing, you must provide written notice to the General Counsel of the Company and the CEO within thirty (30) days after the date on which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason as of such thirtieth day.

6.4Voluntary or Mutual Termination.  You may voluntarily terminate your employment with the Company at any time without Good Reason. If you terminate without Good Reason or if your employment terminates as a result of your death or disability, your salary shall cease on the date of termination and you shall not be entitled to severance, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms of applicable benefit plans.  The continued vesting of any compensatory equity awards held by you shall cease on the termination date, and your right to exercise vested awards (or be issued shares under such vested awards) shall be governed by the terms of the Company’s applicable compensatory equity plans and the corresponding award agreements.

5.

 

 

 

6.5Application of Section 409A.  If the Company (or, if applicable, the successor entity thereto) determines that the severance payments and benefits provided for in this letter agreement (the “Agreement Payments”) constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with any state law of similar effect, “Section 409A”) and you are a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified Employee”), then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Agreement Payments shall be delayed as follows: on the earliest to occur of (i) the date that is six months and one day after the termination date or (ii) the date of your death (such earliest date, the “Delayed Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of the Agreement Payments that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Agreement Payments had not been delayed pursuant to this Section 6.5 and (B) commence paying the balance of the Agreement Payments in accordance with the applicable payment schedules set forth in this letter agreement.  For the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this letter agreement is a separate “payment” for purposes of Section 409A, (2) all Agreement Payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and (3) the Agreement Payments consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation 1.409A-1(b)(9)(v).

7.Change in Control.

7.1Definitions.

(a)“Change in Control” shall mean an Ownership Change Event (as defined below) or a series of related Ownership Change Events (collectively, a “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities of the Company or, in the case of a Transaction described in Section 7.1(b)(iii), the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities.

(b)An “Ownership Change Event” shall be deemed to have occurred if any of the following occurs with respect to the Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company.

6.

 

 

 

7.2Severance.  On the consummation of any Change in Control any remaining unvested portion of your equity awards will be accelerated such that fifty percent (50%) of your outstanding and then-unvested equity awards become fully vested and exercisable as of the date of the Change in Control (the “Acceleration”). If on or within twelve (12) months following a Change in Control, the Company or a successor corporation terminates your employment without Cause and other than as a result of your death or disability, or you resign for Good Reason (a “Change in Control Termination”), and provided that such termination constitutes a Separation from Service, then subject to your obligations below, and in lieu of any severance benefits set forth in Section 6.3 herein, you will be entitled to receive (collectively, the “Change in Control Severance Benefits”):

(a)Subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation for twelve (12) months of the greater of your base salary: (i) in effect as of such termination date; or (ii) as set forth in Section 2.1; or (iii) in effect on the date prior to the Change in Control.  In addition, you will be eligible to receive one hundred and twenty-five percent (125%) of your annual discretionary bonus amount at the higher of that (a) in effect as of such termination date; (b) as set forth in Section 2.2; or (c) in effect on the date prior to the Change in Control, in any case determined as if all performance targets have been satisfied. 

(b)You will receive acceleration of vesting of all of your then-outstanding and then-unvested equity awards as of the date of termination such that the remaining fifty percent (50%) of your unvested equity awards following the Acceleration become fully vested and exercisable. 

(c)If you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to fifteen (15) months following your Separation from Service, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the 60th day following your Separation from Service, the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer's group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease.  

(d)As a precondition of receiving the Change in Control Severance Benefits, you must first sign and make effective on or after the termination date a full, general release of claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit A.

7.3Parachute Payments.

7.

 

 

 

(a)If any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to you or for your benefit, whether under this letter agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the First Reimbursement Payment. 

(b)All determinations required to be made under this Section 7.3 including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the Company or, if such firm declines to serve, such other nationally recognized certified public tax accounting firm as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the Company and you within thirty (30) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the Company and you with an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment.  If the Accounting Firm determines that an Excise Tax is payable with respect to a Payment, it shall furnish to the Company and you an opinion reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up Payment due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date the Company receives the Accounting Firm’s opinion, but in no event later than the end of your tax year following your tax year in which you pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations by the Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall be binding upon the Company and you.

8.General Provisions.

8.1Dispute Resolution.  To aid in the rapid and economical resolution of any disputes that may arise under this letter agreement, the parties agree that any and all claims, disputes or controversies of any nature whatsoever arising from or regarding the interpretation, performance, negotiation, execution, enforcement or breach of this letter agreement, or your relationship with the Company, including statutory claims, shall be resolved by confidential, final and binding arbitration conducted before a single arbitrator with Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in San Francisco, California, in accordance with JAMS’ then-applicable employment arbitration rules (which may be reviewed at www.jamsadr.com/rules-employment-arbitration/). The parties acknowledge that by agreeing 

8.

 

 

 

to this arbitration procedure, they waive the right to resolve any such dispute through a trial by jury, judge or administrative proceeding. The parties will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall bear all JAMS’ arbitration fees and administrative costs in excess of the amount of administrative fees (e.g., filing fees) that you would otherwise be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement shall prevent any party from obtaining injunctive or other provisional relief in court to prevent irreparable harm pending the conclusion of any arbitration proceeding.

8.2Severability.  Whenever possible, each provision of this letter agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this letter agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable consistent with the intent of the parties insofar as possible.

8.3Notices.  Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight courier, to the Company at its primary office location and to you at your address as listed on the Company payroll.

8.4Waiver.  If either party should waive any breach of any provisions of this letter agreement, you or the Company shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this letter agreement.

8.5Entire Agreement.  This letter agreement, together with its exhibits, constitutes the entire and exclusive agreement between you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between you and the Company with regard to this subject matter. It is entered into without reliance on any promise, representation, statement or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended except in a writing signed by you and a duly authorized officer of the Company.  This letter supersedes and replaces all of your prior employment offer letter agreements and employment continuation letter agreements with the Company, (including, without limitation, the offer letter agreement dated June 5, 2017) and all amendments thereto, all of which shall have no further force or effect.

8.6Counterparts.  This letter agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same agreement.

9.

 

 

 

8.7Headings.  The headings of the articles and sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.

8.8Successors and Assigns.  This letter agreement is intended to bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written consent of the Company.

8.9Governing Law.  All questions concerning the construction, validity and interpretation of this letter agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California.

8.10Attorneys’ Fees.  If either party hereto brings any action to enforce your or its rights hereunder, the prevailing party in such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in such action.

To indicate your acceptance of the terms of this letter agreement, please sign this letter agreement in the space provided below and return it to me.  If you have any questions regarding this letter agreement, feel free to contact me.

Sincerely,

CymaBay Therapeutics, Inc.

By: /s/ Sujal Shah

Sujal Shah

President and Chief Executive Officer

Accepted and agreed:

 

 

/s/ Klara Dickinson

Klara Dickinson 

Exhibit A - Release Agreement

10.

 

 

 

Exhibit A

Release Agreement

(To be signed on or after the Separation Date)

I understand that my employment with CymaBay Therapeutics, Inc. (the “Company”) terminated effective _____________________, ____ (the “Separation Date”). The Company has agreed that if I choose to sign this Release Agreement (“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of the employment agreement dated ________________ (as amended, the “Letter Agreement”). I understand that I am not entitled to such severance benefits unless I sign this Release, and it becomes fully effective.

I understand that this Release, together with the Letter Agreement, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated therein.

I hereby confirm my obligations under my Employee Agreement on Confidential Information and Inventions with the Company.

I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already filed a claim.

In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby generally and completely release Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). 

11.

 

 

Nothing in this Release shall prevent me from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in connection with any such proceeding.

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that:  (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release.

I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows:  “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.”  I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder.

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one (21) days following the date it is provided to me.

I accept and agree to the terms and conditions stated above:

 

DateKlara Dickinson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]